Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
8.30
-0.60 (-6.74%)
Aug 14, 2025, 11:42 AM - Market open
Cyclacel Pharmaceuticals Revenue
Cyclacel Pharmaceuticals had revenue of $10.00K in the twelve months ending June 30, 2025, down -87.50% year-over-year. In the year 2024, Cyclacel Pharmaceuticals had annual revenue of $43.00K, down -89.76%.
Revenue (ttm)
$10.00K
Revenue Growth
-87.50%
P/S Ratio
1,409.73
Revenue / Employee
$833
Employees
12
Market Cap
13.15M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CYCC News
- 19 hours ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 days ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 4 weeks ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 5 weeks ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 5 weeks ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 6 weeks ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 7 weeks ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire
- 2 months ago - CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - GlobeNewsWire